
WHAT IS CLAIMED IS


1. A compound of Formula I



Formula I

wherein


A is selected from the group consisting of dibenzocyclooctynyl, cyclooct-4-ynoxyl,



(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyloxy, and ;

D is a maytansinoid;

E is



E4

,

wherein:

J is an amino acid or a peptide;

d, e, g, j, and k are each independently an integer from 1 to 30;


h is an integer from 0 to 30;

Each R^4 is independently selected from the group consisting of H, alkyl, $-N(R^3)_2$, $-SR^3$, C1-C8 alkoxy, and aryl;

Each R^3 is selected from the group consisting of H, and C1-C8 alkyl; and


m is 1;

provided that the compound of Formula I is not




I1.


2. A compound of Formula I according to claim 1, wherein E is selected from the group consisting of




E31;




E32;




E33;




E34;



E35;




E36;




E37

;



E38


; and



E39

.


3. A compound of Formula I according to claim 1 selected from the group consisting of



,


I3

and




I4.

4. A conjugate of Formula III or Formula III' or Formula III''




Formula III

or



Formula III'



Formula III''

wherein:

CB is a cell-binding agent;

M is a non-natural amino acid;


A' is defined as A in any one of claims 1 to 3;

D is a maytansinoid;

E is defined as in any one of claims 1 to 3; and

m is 1 .

5. A conjugate according to claim 4, wherein M exhibits the structure



Formula IV

wherein p and q are each an integer from 0-10;


R^6 is H, amino acid, polypeptide, or a bond;

R^7 is OH, amino acid, polypeptide, or a bond;


V is an alkyl, aryl, carbocycle, heterocycle, or absent; and,

W is O, N, S, or absent.


6. A conjugate according to claim 5, wherein M is selected from the group consisting of




V ;




VI ;




VII ;



VIII ;




IX ; and




X .


7. A compound or conjugate according to any one of claims 1 to 6, wherein the maytansinoid is of the structure



C2

8. A process for preparing a conjugate of Formula III or Formula III' or Formula III'', the process comprising the step of reacting a compound of Formula I with a compound of Formula II





wherein

Formula I is defined as in any one of claims 1 to 3,


with reference to Formula II,

CB is a cell-binding agent; M is a non-natural amino acid; T is an azide group or a tetrazine group; and,

with reference to Formula III and Formula III', and Formula III'',

A' is defined as A in any one of claims 1 to 3.


9. A process according to claim 8 wherein each compound of Formula I is independently selected from the group consisting of



,

I3

and



,

I4.

10. A pharmaceutical composition comprising an effective amount of a conjugate according to any one of claims 4 to 7 and at least one pharmaceutically acceptable excipient.

11. A conjugate according to any one of claims 4 to 7, or the composition of claim 10, for use in the treatment of a disorder in a mammal.